Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cerevel Therapeutics Hldg Inc (NQ: CERE )

44.96 UNCHANGED
Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cerevel Therapeutics Hldg Inc

< Previous 1 2 3 4 5 6 Next >
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Revenue growth during what should be a disastrous patent cliff is encouraging. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024
CERE stock results show that Cerevel Therapeutics Hldg missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed. 
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
Tuesday Talk: Big-Tech Under Attack
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. 
Via Benzinga
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
Via InvestorPlace
Is AbbVie Stock a Buy Now?
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. 
Via The Motley Fool
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. 
Via Benzinga
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
ABBV: This Top Biotech Just Went On A Buying Spree
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
7 Dividend Aristocrats That Will Pay You for Years to Come
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. 
Via InvestorPlace
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
Is AbbVie Stock a Buy Now?
The company is grappling with losing Humira's patent protection in 2023. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
The 7 Most Undervalued Growth Stocks to Buy in December
Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.